Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Mon Mar 31 22:27:56 GMT 2025
by
admin
on
Mon Mar 31 22:27:56 GMT 2025
|
| Protein Type | MONOCLONAL ANTIBODY |
| Protein Sub Type | IGG2 |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
6LGI7RV4PB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
608117
Created by
admin on Mon Mar 31 22:27:56 GMT 2025 , Edited by admin on Mon Mar 31 22:27:56 GMT 2025
|
||
|
FDA ORPHAN DRUG |
608217
Created by
admin on Mon Mar 31 22:27:56 GMT 2025 , Edited by admin on Mon Mar 31 22:27:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB15298
Created by
admin on Mon Mar 31 22:27:56 GMT 2025 , Edited by admin on Mon Mar 31 22:27:56 GMT 2025
|
PRIMARY | |||
|
1822383-81-2
Created by
admin on Mon Mar 31 22:27:56 GMT 2025 , Edited by admin on Mon Mar 31 22:27:56 GMT 2025
|
NO STRUCTURE GIVEN | |||
|
10903
Created by
admin on Mon Mar 31 22:27:56 GMT 2025 , Edited by admin on Mon Mar 31 22:27:56 GMT 2025
|
PRIMARY | |||
|
CHEMBL2109511
Created by
admin on Mon Mar 31 22:27:56 GMT 2025 , Edited by admin on Mon Mar 31 22:27:56 GMT 2025
|
PRIMARY | |||
|
100000178052
Created by
admin on Mon Mar 31 22:27:56 GMT 2025 , Edited by admin on Mon Mar 31 22:27:56 GMT 2025
|
PRIMARY | |||
|
C166947
Created by
admin on Mon Mar 31 22:27:56 GMT 2025 , Edited by admin on Mon Mar 31 22:27:56 GMT 2025
|
PRIMARY | |||
|
2098790-40-8
Created by
admin on Mon Mar 31 22:27:56 GMT 2025 , Edited by admin on Mon Mar 31 22:27:56 GMT 2025
|
PRIMARY | |||
|
6LGI7RV4PB
Created by
admin on Mon Mar 31 22:27:56 GMT 2025 , Edited by admin on Mon Mar 31 22:27:56 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 2_264 | 2_324 |
| 1_264 | 1_324 |
| 1_22 | 1_96 |
| 1_138 | 3_219 |
| 1_151 | 1_207 |
| 1_226 | 2_226 |
| 1_227 | 2_227 |
| 1_230 | 2_230 |
| 1_233 | 2_233 |
| 1_370 | 1_428 |
| 2_22 | 2_96 |
| 2_138 | 4_219 |
| 2_151 | 2_207 |
| 2_370 | 2_428 |
| 3_23 | 3_93 |
| 3_139 | 3_199 |
| 4_23 | 4_93 |
| 4_139 | 4_199 |
| Glycosylation Type | MAMMALIAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_300 |
| N | 2_300 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO ACID REPLACEMENT | [1_1] [2_1] | GLUTAMINE | PIDOLIC ACID | SZB83O1W42 |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(MASS SPECTROMETRY) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|